RT-qPCR and ELISA results demonstrated that BAY11–7082 treatment reduced both the mRNA and protein levels of VEGFA in B7-H3-overexpressing CRC cells compared with the other two inhibitors (Fig. 5b, c). Here, VEGFA is linked to colorectal carcinoma.